ClinicalTrials.gov
public full text
Public Domain
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma#841392
- Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer#256972
- Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.#1047586
- Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin#1164363
- Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma#1162800
Record · ID 853122
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive